Hideko Murooka

Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors

Hideo Ohta, Kōichi Sato, Naoya Murata et al. · Molecular Pharmacology · 2003 · 397 citations

Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of <i>N</i>-Phenyl-<i>N</i>‘-{4-(4-quinolyloxy)phenyl}ureas

Kazuo Kubo, Toshiyuki Shimizu, Shin-ichi Ohyama et al. · Journal of Medicinal Chemistry · 2005 · 143 citations · Full text

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

Hiroaki Ohno, Kazuo Kubo, Hideko Murooka et al. · Molecular Cancer Therapeutics · 2006 · 98 citations · Full text

Osteolytic Bone Destruction, Sclerostin, Orthopaedic Surgery +15

The orally‐active and selective c‐Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen‐induced arthritis mouse model

Hiroaki Ohno, Yasunori Uemura, Hideko Murooka et al. · European Journal of Immunology · 2007 · 63 citations · Full text

Disease Progression, Immunology, Cell Death +20

The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis

Yasunori Uemura, Hiroaki Ohno, Yumiko Ohzeki et al. · Journal of Neuroimmunology · 2008 · 31 citations

Autoimmune Disease, Receptor Tyrosine Kinase, Immunology +9